CASI - CASI Pharmaceuticals Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

CASI Pharmaceuticals Inc. (CASI) - corporate logo

CASI Pharmaceuticals is implementing eco-friendly packaging standards and minimizing harmful emissions during drug synthesis. CASI Pharmaceuticals generates profit by adapting Western target molecules to PRC regulations, leveraging the low demand elasticity within onco-hematology. The EV/EBITDA market trend at 0.00 complements data on stable management, which effectively integrates the drug portfolio into state healthcare networks.

CASI CASI Pharmaceuticals Inc.: Company Value to EBITDA in the range 11/23/2025 - 03/14/2026

casipharmaceuticals.com - analytical breakdowns and key metrics (CASI)

- current price and projected stock value:
Stock Price CASI Pharmaceuticals, Inc.|CASI - Price Target Chart
- market capitalization statistics:
Market Value CASI Pharmaceuticals, Inc|CASI - Total Company Value
- book value of equity indicators:
Net Assets per Single Share CASI Pharmaceuticals|CASI - Total Stockholders' Equity|Market Value to Book Value Ratio casipharmaceuticals.com|CASI - Company Assets
- business debt structure and liquidity details:
Total Debt to Capital CASI Pharmaceuticals|CASI - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital CASI Pharmaceuticals, Inc.|CASI - Company Total Debt|Debts to Book Capitalization CASI Pharmaceuticals, Inc|CASI - Company Long-Term Debts|Company Short-Term Debt CASI Pharmaceuticals|Quick Ratio casipharmaceuticals.com
- business earnings and investment ratios data:
CASI - Net Financial Result|Future Profit CASI Pharmaceuticals|CASI - Company Value to Net Income|Future Price to Earnings CASI Pharmaceuticals, Inc.|CASI - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple CASI Pharmaceuticals, Inc|CASI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) CASI Pharmaceuticals|CASI - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months casipharmaceuticals.com|CASI - Earnings per share increase in current year|Net earnings per share growth forecast for next year CASI Pharmaceuticals
Analysis of all company metrics:CASI Pharmaceuticals, Inc CASI
Product sample of casipharmaceuticals.com

To assess an asset's operational resilience, an investor analyzes the ratio of enterprise value to earnings before interest, taxes, depreciation, and amortization, which allows the EV/EBITDA multiple chart to determine the degree of price overheating relative to actual cash flows. In the case of CASI Pharmaceuticals (CASI), this metric confirms the effectiveness of commercializing Wei-Wu He's Western innovations by linking market capitalization to the growth rates of the drug portfolio.

Competitors of CASI Pharmaceuticals

EV/EBITDA Multiple TGTX (TG Therapeutics Corp)|Arcellx Therapeutics - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SNDX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Kura Oncology (KURA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA ADC Therapeutics S.A. (ADCT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Foghorn Therapeutics, Inc.|Company Value to EBITDA Vor Bio Inc. VOR|EV/EBITDA Multiple NKTX|coeptistx.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATNM (Actinium Pharmaceuticals, Inc.)|ESLA - Enterprise Value to EBITDA Ratio|Marker Bio - EV/EBITDA Multiple|INAB - EV/EBITDA Multiple|eternatx.com (ERNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GTBP - Total Company Value to Operating Income Before Depreciation Ratio|APTO (Aptose Biosciences Inc) - EV/EBITDA Multiple|Bio-Path Holdings Inc. (BPTH) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MEIP (MEI Pharma Corp)|VINC (vincerx.com) - Business Value to Operating Income Before Depreciation